AKT1 and non-small cell lung carcinoma: To test this hypothesis, a phase study II trial of Ipatasertib, a novel highly selective ATP-competitive pan-Akt inhibitor, in combination with docetaxel in advanced NSCLC patients progressed to first-line immunotherapy is currently ongoing (NCT04467801).